DAVENPORT & Co LLC Has $25.91 Million Position in Eli Lilly and Company $LLY

DAVENPORT & Co LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,138 shares of the company’s stock after purchasing an additional 2,080 shares during the period. DAVENPORT & Co LLC’s holdings in Eli Lilly and Company were worth $25,908,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in Eli Lilly and Company in the second quarter worth about $27,000. Evolution Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $29,000. Steph & Co. lifted its holdings in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after acquiring an additional 29 shares during the period. Finally, Financial Gravity Companies Inc. bought a new position in Eli Lilly and Company during the 2nd quarter valued at about $31,000. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LLY. Morgan Stanley lifted their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Deutsche Bank Aktiengesellschaft increased their target price on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Scotiabank started coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price target on the stock. Finally, Daiwa America raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 16th. Four analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,155.36.

Eli Lilly and Company Trading Up 0.5%

Shares of Eli Lilly and Company stock opened at $1,077.06 on Friday. The company has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.69, a P/E/G ratio of 1.09 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The business has a fifty day simple moving average of $981.27 and a two-hundred day simple moving average of $839.03. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the business earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.